Summary
Elevated serum levels of intact parathyroid hormone (PTH) have been reported in severe versus mild biliary cirrhosis. The aim of this study was to determine whether hyperparathyroidism was present in severe liver disease on the basis of the inability of the liver to catabolize the hormone. Because biologic activity resides in the amino terminal, and amino terminal PTH determinations have not been routinely made in liver disease, it is possible that hyperparathyroidism was previously missed in these patients. Accordingly, we obtained fasting blood from 11 patients with severe liver disease and 8 age-matched controls. We measured intact, amino terminal, and mid-region PTH, vitamin D metabolites, bone gamma carboxyglutamic acid protein (BGP), ionized calcium, phosphorus, magnesium, and liver function tests. Serum levels of PTH were normal with all assays and 1,25(OH)2D levels were not elevated. These findings argue against the possibility that hyperparathyroidism plays a role in the pathogenesis of hepatic osteodystrophy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Atkinson MJ, Vido I, Keck E, Hesch RD (1983) Hepatic osteodystrophy in primary biliary cirrhosis: a possible defect in Kupffer cell mediated cleavage of parathyroid hormone. Clin Endocrinol 18:21–28
Potts, JT Jr, Kronenberg HM, Rosenblatt M (1982) Parathyroid hormone: chemistry, biosynthesis, and mode of action. Adv Prot Chem 35:323–396
Slatopolsky E, Martin K, Morrissey J, Hruska K (1982) Current concepts of the metabolism and radioimmunoassay of parathyroid hormone. J Lab Clin Med 99:309–316
Segre GV (1983) Amino-terminal radioimmunoassays for human parathyroid hormone. In: Frame B, Potts JT Jr (eds) Clinical disorders of bone and mineral metabolism. Excerpta Medica, Amsterdam, pp 14–17
Potts JT Jr, Segre GV, Endres DB (1983) Current clinical concepts: assessment of parathyroid function with an N-terminal specific radioimmunoassay for intact parathyroid hormone. Nichols Institute, San Juan Capistrano, California, p 1
Freitag J, Martin KJ, Hruska KA, Anderson C, Conrades M, Laderson J, Klahr S, Slatopolsky E (1978) Impaired parathyroid hormone metabolism in patients with chronic renal failure. N Engl J Med 298:29–32
Herlong HF, Recker RR, Maddrey WC (1982) Bone disease in primary biliary cirrhosis: histologic features and response to 25-hydroxyvitamin D. Gastroenterology 83:103–108
Bouillon R, Dekeyser L, Auwerx J, Van Buelen H (1984) The influence of DBP on the serum concentrations of vitamin D metabolites in patients with liver cirrhosis or nephrotic syndrome (abstract) In: Cohn DV, Potts JT Jr, Fujita T, Talmage RV (eds) Endocrine control of bone and calcium metabolism. Excerpta Medica, Amsterdam 8A:399
Diamond TH, Stiel D, Lunzer M, McDowall D, Eckstein RP, Posen S (1989) Hepatic osteodystrophy: static and dynamic bone histomorphometry and serum bone gla-protein in 80 patients with chronic liver disease. Gastroenterology 96:213–221
Endres DB, Morgan CH, Garry PJ, Omdahl JL (in press) Age-related changes in serum immunoreactive parathyroid hormone and its biological action in healthy men and women. J Clin Endocrinol Metab
Mallette LE, Tuma SN, Berger RE, Kirkland JL (1982) Radioimmunoassay for the middle region of human parathyroid hormone using an homologous serum with a carboxyl fragment of bovine parathyroid hormone as radioligand. J Clin Endocrinol Metab 54:1017–1024
Nussbaum SR, Potts, JT, Wang CA, Azhradnik R, Lavigne JR, Kim L, Segre GV (1987) Development of a highly sensitive 2 site immunoradiometric assay for parathyroid hormone and its clinical utility in the evaluation of patients with hypercalcemia (abstract). 69th Ann Meeting of the Endocrine Society, June 10–12, 1987, Indianapolis, Indiana
Lu J, Endres D, Mueller J, Broughton A (1982) Development and evaluation of an accurate, sensitive method for the determination of serum 25-hydroxyvitamin D (abstract). Clin Chem 28:1592
Reinhardt TA, Horst RL, Orf JW, Hollis BW (1984) A microassay for 1,25-dihydroxyvitamin D not requiring high performance liquid chromatography: application to clinical studies. J Clin Endocrinol Metab 58:91–98
Christiansen C, Nilas L, Riis BJ, Rodbro P, Deftos L (1985) Uncoupling of bone formation and resorption by combined estrogen and progestogen therapy in postmenopausal osteoporosis. Lancet II:800–801
Deftos LJ, Parthemore JG, Price PA (1982) Changes in plasma bone GLA protein during treatment of bone disease. Calcif Tissue Int 34:121–124
Bengoa JM, Sitrin MD, Meredith S, Kelly SE, Shah N, Baker AL, Rosenberg IH (1984) Intestinal calcium absorption and vitamin D status in chronic cholestatic liver disease. Hepatology 4:261–265
Mobarhan SA, Russell RM, Recker RR, Posner DB, Iber FL, Miller P (1984) Metabolic bone disease in alcoholic cirrhosis: a comparison of the effect of vitamin D2, 25-hydroxyvitamin D3, or supportive treatment Hepatology 4:266–273
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Klein, G.L., Endres, D.B., Colonna, J.D. et al. Absence of hyperparathyroidism in severe liver disease. Calcif Tissue Int 44, 330–334 (1989). https://doi.org/10.1007/BF02556312
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF02556312